Ligand Pharmaceuticals (LGND) Shares Outstanding (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Shares Outstanding (Entity) data on file, last reported at $20.0 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Entity) rose 3.91% year-over-year to $20.0 million; the trailing twelve-month figure through Mar 2026 stood at $20.0 million (up 3.91% YoY), and the FY2025 full-year result was $19.8 million, up 3.5% from the prior year.
• Shares Outstanding (Entity) improved to $20.0 million in Q1 2026, from $19.8 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $20.0 million in Q1 2026 to a low of $16.9 million in Q1 2022.
• A 5-year average of $18.2 million and a median of $17.9 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) grew 1.1% in 2022 and grew 8.83% in 2024, its largest moves.
• Tracing LGND's Shares Outstanding (Entity) over 5 years: stood at $17.0 million in 2022, then climbed by 3.57% to $17.6 million in 2023, then gained by 8.83% to $19.1 million in 2024, then gained by 3.5% to $19.8 million in 2025, then rose by 1.29% to $20.0 million in 2026.
• Business Quant data shows LGND's Shares Outstanding (Entity) at $20.0 million in Q1 2026, $19.8 million in Q4 2025, and $19.7 million in Q3 2025.